TY - JOUR
T1 - Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
AU - Martino, Massimo
AU - Bottini, Alberto
AU - Rosti, Giovanni
AU - Generali, Daniele
AU - Secondino, Simona
AU - Barni, Sandro
AU - Maisano, Roberto
AU - Lanza, Francesco
AU - Castagna, Luca
AU - Pedrazzoli, Paolo
PY - 2012
Y1 - 2012
N2 - Introduction: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. Areas covered: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. Expert opinion: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC.
AB - Introduction: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. Areas covered: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. Expert opinion: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC.
KW - Autologous hematopoietic progenitor cell transplantation
KW - High-dose chemotherapy
KW - High-risk breast cancer
KW - Metastatic breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84867285965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867285965&partnerID=8YFLogxK
U2 - 10.1517/14712598.2012.721767
DO - 10.1517/14712598.2012.721767
M3 - Article
C2 - 22946512
AN - SCOPUS:84867285965
VL - 12
SP - 1505
EP - 1515
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 11
ER -